{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:36:58Z","timestamp":1774366618025,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.clinthera.2010.03.008","type":"journal-article","created":{"date-parts":[[2010,4,18]],"date-time":"2010-04-18T14:57:52Z","timestamp":1271602672000},"page":"556-574","source":"Crossref","is-referenced-by-count":13,"title":["Mycophenolate mofetil 500-mg tablet under fasting conditions: Single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects"],"prefix":"10.1016","volume":"32","author":[{"given":"Susana","family":"Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Filipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina Franco","family":"Sp\u00ednola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Torns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.03.008_bib3","author":"Franco Spinola"},{"key":"10.1016\/j.clinthera.2010.03.008_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.clinthera.2010.03.008_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.ftd.0000163949.40686.0f","article-title":"Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients","volume":"27","author":"Armstrong","year":"2005","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.clinthera.2010.03.008_bib13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2217\/14622416.9.7.869","article-title":"Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers","volume":"9","author":"Levesque","year":"2008","journal-title":"Pharmacogenomics."},{"key":"10.1016\/j.clinthera.2010.03.008_bib14","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jps.2600821125","article-title":"Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies","volume":"82","author":"Blume","year":"1993","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.clinthera.2010.03.008_bib15","article-title":"Highly variable drugs and highly variable drug products. Briefing on regulatory and scientific perspectives","author":"Sp\u00ednola","year":"2009","journal-title":"EUFEPS BABP Network open discussion: Revised European guidelines on bioequivalence. Bonn, Germany"},{"key":"10.1016\/j.clinthera.2010.03.008_bib16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0091270007300954","article-title":"Replicate study design in bioequiva- lency assessment, pros and cons: Bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation","volume":"47","author":"Karim","year":"2007","journal-title":"J Clin Pharmacol."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T20:24:10Z","timestamp":1544559850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810000998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0149291810000998"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.03.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}